Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

309 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characteristics of triple-negative breast cancer.
de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC. de Ruijter TC, et al. J Cancer Res Clin Oncol. 2011 Feb;137(2):183-92. doi: 10.1007/s00432-010-0957-x. Epub 2010 Nov 11. J Cancer Res Clin Oncol. 2011. PMID: 21069385 Free PMC article. Review.
Taxane resistance in breast cancer: a closed HER2 circuit?
de Hoon JP, Veeck J, Vriens BE, Calon TG, van Engeland M, Tjan-Heijnen VC. de Hoon JP, et al. Biochim Biophys Acta. 2012 Apr;1825(2):197-206. doi: 10.1016/j.bbcan.2012.01.001. Epub 2012 Jan 18. Biochim Biophys Acta. 2012. PMID: 22280939 Review.
Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer.
Vriens BE, Aarts MJ, de Vries B, van Gastel SM, Wals J, Smilde TJ, van Warmerdam LJ, de Boer M, van Spronsen DJ, Borm GF, Tjan-Heijnen VC; Breast Cancer Trialists' Group of the Netherlands (BOOG). Vriens BE, et al. Eur J Cancer. 2013 Oct;49(15):3102-10. doi: 10.1016/j.ejca.2013.06.012. Epub 2013 Jul 10. Eur J Cancer. 2013. PMID: 23850450 Clinical Trial.
A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer.
Schipper RJ, Moossdorff M, Nelemans PJ, Nieuwenhuijzen GA, de Vries B, Strobbe LJ, Roumen RM, van den Berkmortel F, Tjan-Heijnen VC, Beets-Tan RG, Lobbes MB, Smidt ML. Schipper RJ, et al. Clin Breast Cancer. 2014 Oct;14(5):315-22. doi: 10.1016/j.clbc.2013.12.015. Epub 2014 Jan 3. Clin Breast Cancer. 2014. PMID: 24548732
Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium.
Seferina SC, Lobbezoo DJ, de Boer M, Dercksen MW, van den Berkmortel F, van Kampen RJ, van de Wouw AJ, de Vries B, Joore MA, Peer PG, Voogd AC, Tjan-Heijnen VC. Seferina SC, et al. Oncologist. 2015 Aug;20(8):856-63. doi: 10.1634/theoncologist.2015-0006. Epub 2015 Jun 22. Oncologist. 2015. PMID: 26099745 Free PMC article.
Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer.
Vriens BE, de Vries B, Lobbes MB, van Gastel SM, van den Berkmortel FW, Smilde TJ, van Warmerdam LJ, de Boer M, van Spronsen DJ, Smidt ML, Peer PG, Aarts MJ, Tjan-Heijnen VC; INTENS Study Group. Vriens BE, et al. Eur J Cancer. 2016 Jan;52:67-76. doi: 10.1016/j.ejca.2015.10.010. Epub 2015 Nov 30. Eur J Cancer. 2016. PMID: 26650831 Clinical Trial.
309 results